TrialTransplantation2026

Safety, Pharmacokinetics, and Pharmacodynamics of Fixed-dose, Subcutaneous, and Intravenous Administration of VEL-101, an Anti-CD28 PEGylated Monoclonal Antibody Fragment, in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase 1 Study.

Simon Tremblay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.